In contrast, after evaluating myeloblastin with immunohistochemistry, no significant differential expression was observed between MPN-DLBCL and R-DLBCL sections (p = 0.297) (Figure 2M,N). This evidence concerns the gene PRTN3 and myeloproliferative disorder.